Can Carboplatin Be Safely Omitted in Neoadjuvant HER2-Positive Breast Cancer? Evidence, Patient Selection, and Practice Impact

For patients with neoadjuvant HER2+ breast cancer, clinicians are increasingly reconsidering whether carboplatin a platinum chemotherapy drug sometimes added to preoperative regimens is necessary. The conversation matters because removing an agent that adds toxicity could change patient experience, resource use, and long-term outcomes without lowering cure rates.

Why It Matters

HER2-positive breast cancer is another example where a significant breakthrough was achieved in targeted oncology. The treatment methods targeting HER2 are highly effective when it comes to HER2-overproducing cancers. In neoadjuvant therapy, anti-HER2 therapy drugs are used in combination with chemotherapeutic agents in order to reduce the size of tumors prior to their surgical removal and to evaluate early on the effectiveness of such treatment. Carboplatin is often included into treatment regimen as platinating drugs sensitize tumors to chemotherapies.

Yet carboplatin is anything but harmless. Not only does it cause direct damage in the form of lowered blood counts, leading to increased risk of infections and hospitalization but it is also associated with longer-lasting effects such as fatigue and, in some instances, fertility-related issues. The choice facing doctors and patients here is tricky: is the marginal benefit of potentially increasing the effectiveness of cancer treatment worth additional risks and expenses? If the answer is negative, the absence of carboplatin from the treatment scheme would be an easy way to avoid suffering.

Beyond the individual patient level, there are broader implications associated with the issue. Capacity within oncology infusions, nursing capacity, and supportive care capabilities may be influenced by choosing to increase or decrease chemotherapy intensity. By decreasing excessive use of chemotherapy, costs for medication and treatment, decreased transfusion needs, and decreased strain on capacity in cancer centers could be minimized. On the other hand, if this approach is not indicated for certain patients, an under-use of chemotherapy may become complicated at a later stage.

Who It Affects

The patients who will receive neoadjuvant therapy based on HER2 status are the ones that will be directly impacted by the findings of this study. It encompasses all different types of tumors, including small tumors where breast conservation can be done, as well as large tumors where reduction through neoadjuvant therapy will facilitate surgical removal. The risk-to-benefit ratio of administering carboplatin may vary among the patients due to their age, presence of comorbidities, hematological parameters, as well as fertility goals.

The medical oncologists and tumor multidisciplinary teams will have to adjust their methods of discussing treatment and care. The surgeons and radiation oncologists depend on the reduction and the response of the tumors for deciding on the extent of surgery and adjuvant treatments; this means a change in the method will affect the downstream decisions. The nurses and pharmacists will have to make alterations in their schedule of infusions. Other parties like the payers and health care providers are stakeholders since the choice of drug will affect them too.

Equity issues exist as well. Patients who live in areas where there is a lack of access to centers that see many cancer patients can suffer more from the increased therapy due to a lack of support services. However, if treatment is simplified, this may allow for greater access for patients and less need for trips to clinics for infusions or appointments.

What Changes

• Clinicians may offer simplified neoadjuvant regimens that omit carboplatin for selected patients, emphasizing shared decision-making about the trade-offs between potential increased tumor response and added toxicity.
• Care teams will place greater emphasis on individual risk assessment — including age, comorbidities, fertility concerns, and tumor biology — to decide who is a candidate for omission versus continued use of platinum therapy.
• Health systems and payers will be prompted to update pathways and coverage policies to support de‑escalation where appropriate, while ensuring measures are in place to monitor outcomes and catch any unintended harms.
• Research and quality programs will likely accelerate work on biomarkers and early-response tools that identify patients who can safely avoid extra chemotherapy, enabling more personalized neoadjuvant strategies.

The treatment plan must be pragmatic and centered around the needs of the patient. During the consultation with the single patient, the healthcare providers must describe the potential benefits associated with using carboplatin, for instance, its minor contribution to achieving a complete response, and whether such a potential benefit outweighs the increased risks of experiencing the adverse events. The discussion must address the major side effects caused by carboplatin, such as neutropenia, fatigue, nausea, and the increased risk of developing infections, and the management strategies to be used in dealing with such complications.

Equally significant, however, are the implications in case of exclusion of carboplatin from the treatment protocol. It might turn out that the surgical intervention will remain the same or be different since the tumor response will differ from expectations. The subsequent actions may then depend upon the amount of the malignant cells present after the surgical intervention. For most patients, there is an expectation of clear responses regarding trade-offs, such as difficulty of weekly treatment regimens, potential complications associated with side effects, which would lead to the postponement of the procedures, and even long-term risks including the risk of infertility and permanent fatigue, among others.

Practically speaking, implementation of omission of carboplatin will necessitate revised clinical guidelines. In oncology settings, there will be the need for a common framework regarding criteria used to determine eligibility for omission, methods to monitor patients’ responses to treatment, and strategies to address any early warning signs of poor response to treatment. Tumor board discussions might be more involved where decisions become difficult. Most importantly, there must be a mechanism for data gathering to ensure that outcomes following de-escalation therapy are tracked.

From a policy point of view, guideline groups and insurance payers will feel pressure to keep up with the new evidence and decide how it should affect coverage and standard treatment pathways. In the past, guidelines have sometimes been slow to adopt “less treatment” approaches, even when the data looked strong. That delay can leave doctors stuck in a gray zone, where some clinics de-escalate and others don’t—so patients may get different care depending on where they’re treated.

Payers will also want a clear message: is skipping carboplatin supported by real outcomes, not just short-term response rates? At the same time, strict “one-rule-for-everyone” payment policies could backfire. If reimbursement rules are too rigid, they may discourage careful, patient-by-patient decisions that could reduce side effects, avoid hospital visits, and lower overall costs.

A more helpful approach is to create policies that support smart de-escalation: encourage clinics to track results (response, complications, recurrence patterns) and use shared decision-making tools so patients understand the pros and cons. When policy supports both outcome monitoring and patient-centered conversations, it becomes easier to adopt safer, more consistent care without forcing every patient into the same treatment plan.

For the future, however, the field of HER2+ breast cancer management is heading towards becoming more personalized. The use of better biomarkers to predict responses, non-invasive ways to monitor patients through circulating tumor DNA analysis, and improved imaging techniques may eventually allow identification of the patients that need extra chemotherapy and those that don’t. Once these become more established, the aim will be to provide a more tailored approach to therapy, thus avoiding harmful effects without compromising on great results.

Finally, there should be survivorship care planning involved in any modification to the existing standard of care. Even without carboplatin, the patients will require care for heart damage due to HER2-based therapies, neuropathy and other side effects related to chemotherapeutic agents, and psychosocial issues. With the increasing frequency of the procedure, survivors can allocate their survivorship care plan to focus on physical therapy, fertility preservation counseling, and follow-up care.

In conclusion, the minimization or exclusion of carboplatin from the pre-surgical therapy of HER2+ breast cancer may be a considerable step towards more humane and personalized cancer care – provided that proper patient selection, adequate communication between the physician and patient, and necessary infrastructure modifications are made to avoid deterioration of patient outcomes.

References:

1. Gao H-F, Ye G-L, Lin Y, Huang Q, Dong J, Cao Y, et al. Neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in human epidermal growth factor receptor 2–positive breast cancer: the randomized noninferiority phase III neoCARHP trial. Journal of Clinical Oncology. 2026. Available from: https://ascopubs.org/doi/pdf/10.1200/JCO-25-02176
2. Wu S, Bian L, Wang H, Zhang S, Wang T, Yu Z, et al. De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China. World Journal of Surgical Oncology. 2024;22:214. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11337883/
3. U.S. Food and Drug Administration. KYXATA™ (carboplatin) injection, for intravenous use: prescribing information (label). 2025. Available from: https://www.accessdata.fda.gov/drugsatfda\_docs/label/2025/219921s000lbl